课题基金 / 基金详情

Improving outcomes of patients with advanced prostate cancer through a better understanding of provider decision-making

Improving outcomes of patients with advanced prostate cancer through a better understanding of provider decision-making
通过更好地了解医疗服务提供者的决策来改善晚期前列腺癌患者的治疗结果
批准号:
10654860
负责人:
Deborah R. Kaye
金额:
$14.48万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-01 至 2027-06-30

项目摘要

项目成果

Deborah R. Kaye的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT Candidate: Deborah Kaye, MD, MS is a urologic oncologist and junior health services researcher focused on improving the outcomes for patients with cancer. Dr. Kaye’s long-term goal is to become an independent surgeon-scientist with expertise in quantitative and qualitative research methods, an in- depth understanding of provider decision-making and intervention and clinical trial design, in order to devise, evaluate and implement effective health care policies to improve the lives of patients with cancer. Research Context: Numerous systemic therapies have recently been approved for the treatment of advanced prostate cancer, demonstrating modest improvements in median survival fromtwo to five months. Unfortunately, little is known regarding which therapies, or combinations of therapies, are most effective. What is known, however, is that each option differs significantly in route of administration, side effects, and price. Currently, treatment for advanced prostate cancer varies significantly based on provider specialty and location, and patient race and income. With sparse comparative effectiveness evidence, treatment recommendations rely heavily on physician preference and experience, which likely contributes to differential patient outcomes and payment disparities. Economic and non-economic drivers of provider decision-making remain a critical knowledge gap in advanced prostate cancer. Moreover, few interventions exist to decrease the out-of-pocket payments, and therefore potentially improve outcomes for patients with advance prostate cancer. Specific Aims: 1) To determine the factors contributing to provider decision-making for initial choice of systemic therapy for advanced prostate cancer. 2) To develop a cost-transparency intervention to decrease patient OoP payments for advanced prostate cancertreatment. 3) To pilot test the feasibility, acceptability, usability and initial signals of efficacy of a cost-transparency intervention. Research Plan: Dr. Kaye will use qualitative research methods (focus groups, patient and provider interviews) to determine the factors impacting provider decision-making and type of first-line systemic therapy received, and use iterative intervention design to devise a cost-transparency intervention to lower patient out-of-pocket payments and improve outcomes for patients with advanced prostate cancer. Finally, this proposal will test the feasibility, acceptability, usability and initial signals of efficacy of the cost-transparency intervention with a two- arm randomized pilot trial Career Development Plan: In parallel with the outlined research plan and under the guidance of experienced mentors, Dr. Kaye will develop expertise in: 1) provider decision-making; 2) qualitative research methods; 3) intervention and clinical trial design.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Drug costs: acquisition costs are critical but not the entire story of financial toxicity.
药品成本:采购成本至关重要,但并不是财务毒性的全部。
DOI: 10.1111/bju.16092
发表时间: 2023
期刊: BJU international
影响因子: 4.5
作者: [Kaye,DeborahR]
通讯作者: Kaye,DeborahR
Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
保险公司和患者为治疗转移性去势抵抗性前列腺癌支付的药物费用。
DOI: 10.1200/op.22.00645
发表时间: 2023
期刊: JCO oncology practice
影响因子: 4
作者: [Kaye,DeborahR, Lee,Hui-Jie, Gordee,Alexander, George,DanielJ, Ubel,PeterA, Scales,CharlesD, Bundorf,MKate]
通讯作者: Bundorf,MKate
Improving outcomes of patients with advanced prostate cancer through a better understanding of provider decision-making
  • 批准号:
    10525118
  • 项目类别:
  • 资助金额:
    $14.48万
  • 财政年份:
    2022
  • 负责人:
    Deborah R. Kaye
  • 依托单位:
海外基金